The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Affiliation
Jagiellonian University Medical College
Country
Poland
1. Current Status, Position
Dr Bochenek (MD, MPH, PhD) Assistant Professor at the Department of Drug Management, Institute of Public Health, Jagiellonian University, Krakow, Poland. Member of the Economic Commission, advisory body to the Minister fo Health.
2. Education
Dr Tomasz Bochenek is the author and co-author of original research papers, author of academic textbooks and a contributor of special focus chapters into a number of publications. Involved in the pursuit and management of public health projects and in monitoring clinical trials (in the past). Co-organiser and co-ordinator of diverse training schemes for medical professionals. Senior editor, academic editor and member of scientific board of specialist journals for health care professionals. Senior consultant in nationwide projects aimed at restructuring Polish public health care system. In the period spanning 1998-2006 appointed the first Managing Director at the Department of Pharmaceuticals and Medical Devices, the Malopolska Regional Sickness Fund and the Malopolska Provincial Branch of the National Health Fund. He completed his medical graduate studies in Poland (Jagiellonian University, Krakow) and pursued further education at Hartford University and Harvard University, USA; University of Liege, Belgium; University of Sheffield, UK; Maastricht University, The Netherlands; Nordic School of Public Health, Sweden; universities of the Baltic states, striving throughout to broaden the scope of his professional experience and expertise.
3. Research Area
The scope of his professional interests embraces pharmaceutical policy, pharmaceutical pricing and reimbursement, management of pharmaceuticals and medical devices, pharmacoeconomics and health technologies assessment.
4. Conflict of interest: none